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Short Title: JAM-A and breast cancer  
Key words: junctional adhesion molecule-A; breast cancer; tight junction; migration. 
Journal Category: Cancer Cell Biology 
Statements: Our manuscript shows a novel association between high gene/protein expression of 
the epithelial tight junction protein Junctional Adhesion Molecule-A (JAM-A) and poor 
prognosis in primary breast carcinoma patients.   Mechanistically we demonstrate that JAM-A 
knockdown decreases the motility of breast cancer cells, potentially resulting from a concomitant 
reduction in β1-integrin protein levels. We suggest that the impact of our finding lies in the future 
consideration of JAM-A as a target to prevent tumor cell dissemination in breast cancer patients.  
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Abbreviations: 
ATCC, American Type Culture Collection; DMEM, Dulbecco’s modified Eagle’s medium; 
ECACC, European Centre of Animal Cell Cultures; ER, estrogen receptor; EV, empty vector; 
IDC, invasive ductal carcinoma; IHC, immunohistochemistry; ILC, invasive lobular carcinoma; 
JAM-A, junctional adhesion molecule-A; NF, non-functioning; NHG, Nottingham Histological 
Grade; PR, progesterone receptor; shRNA, short hairpin ribonucleic acid;  TJ, tight junction; 
TMA, tissue microarray; VEGF, vascular endothelial growth factor; VEGFR1, vascular 
endothelial growth factor receptor 1; VEGFR2, vascular endothelial growth factor receptor 2. 
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ABSTRACT  
The cell-cell adhesion protein junctional adhesion molecule-A (JAM-A) influences epithelial cell 
morphology and migration. As migration is required for tumor cell invasion and metastasis, we 
sought to elucidate the role of JAM-A in invasive breast cancer. A breast cancer tissue 
microarray was analyzed for JAM-A protein expression, in parallel with analysis of JAM-A gene 
expression data from a breast cancer clinical dataset. Our data demonstrate a novel association 
between JAM-A gene and protein upregulation and poor prognosis in breast cancer. To 
mechanistically dissect this process, we used lentiviral technology to stably knock down JAM-A 
gene expression by shRNA in MCF7 breast cancer cells, which express high endogenous levels 
of JAM-A. We also antagonised JAM-A function in wild-type MCF7 cells using an inhibitory 
antibody which blocks JAM-A dimerization. Knockdown or functional antagonism of JAM-A 
decreased breast cancer cell migration in scratch-wound assays. Reductions in β1-integrin protein 
levels were observed following JAM-A-knockdown in MCF7 cells, suggesting a mechanism for 
reduced motility after loss of JAM-A. Consistent with this hypothesis, tissue microarray analysis 
of β1-integrin protein expression in invasive breast cancer tissues revealed a trend toward high 
β1-integrin protein levels being indicative of poor prognosis. 22% of patients were observed to 
co-express high levels of JAM-A and β1-integrin protein, and MDA-MB-231 breast cells stably 
over-expressing JAM-A showed an increase in β1-integrin protein expression. Our results are 
consistent with a previously unreported role for JAM-A over-expression as a possible mechanism 
contributing to progression in primary breast cancer, and a potential therapeutic target. 
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INTRODUCTION 
Epithelial polarity is maintained by multi-protein adhesion complexes at cell-cell interfaces, 
including tight junctions (TJs) 1.  Dysregulation of individual TJ proteins (eg. claudins, ZO-1) 
have been implicated in the loss of tissue architecture and polarity associated with breast 
carcinoma and other malignancies 2, 3.  
 
The junctional adhesion molecule (JAM) family of TJ proteins are type 1 transmembrane proteins 
of the immunoglobulin superfamily 4.  There are five characterised JAM family proteins, JAM-A, 
JAM-B, JAM-C, JAM-4, and JAM-L, which are expressed in various tissues throughout the body 
and on the surfaces of platelets, erythrocytes and leukocytes 5.  JAM proteins are known to have 
important regulatory functions in numerous cellular adhesive processes including platelet 
activation 6, leukocyte migration 7, 8, angiogenesis 9, intercellular junction assembly 10 and cell 
morphology 11.  Much evidence indicates an important role for JAM proteins in regulating and 
maintaining tight junctions through associations with proteins such as ZO-1, AF6, and PAR3 5. 
Interestingly, JAM-A has also been identified as the epithelial receptor for the pathogen reovirus 
12
. 
 
As JAM family members form an important scaffold for assembly of other TJ proteins 5, it is 
plausible that loss of this key protein could facilitate cell-cell dissociation and promote invasive 
phenotypes in solid tumors.  JAM-A expression has been previously shown to reduce 
spontaneous and random motility of endothelial cells 13.  Indeed, a recent publication reported for 
the first time an association between loss of junctional adhesion molecule-A (JAM-A) and the 
acquisition of invasive properties in breast cancer cells 14.  In this study Naik et al. hypothesised 
that JAM-A loss could potentially predict poor clinical outcome in breast cancer 14.  It is likely 
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that tight junction protein expression must be carefully balanced for normal cell function. 
However, it is also likely that numerous extrinsic signals from the tumour microenvironment may 
influence tight junction protein expression and function in tumour epithelial cells in vivo. 
 
Thus to acknowledge the complexity of the in vivo breast cancer microenvironment, our current 
study has predominantly focused upon searching for associations between JAM-A expression and 
prognostic outcome in breast cancer clinical datasets.  Analysis of a 270-patient invasive breast 
cancer tissue microarray (TMA) revealed a strong correlation between high JAM-A protein 
expression and reduced patient  survival.  Re-analysis of the independent van de Vijver breast 
cancer DNA microarray dataset (n = 295) 15 to focus on JAM-A gene expression supported our 
findings.  Our mechanistic studies showed that knockdown or functional antagonism of JAM-A 
in MCF7 breast cancer cells significantly decreased cell migration.  As β1-integrin protein levels 
were reduced in JAM-A knockdown cells, our data suggest that loss of β1-integrin may be one 
possible mechanism to explain observed reductions in cell migration downstream of JAM-A loss. 
In support of this, β1-integrin has been shown to regulate cell spreading 11 and the malignant 
phenotype in breast cancer cells 16, and antagonism of β1-integrin inhibits cell migration 17.  In 
fact our invasive breast cancer TMA showed a correlation between high expression of β1-integrin 
and poor prognosis; and JAM-A over-expressing MDA-MB-231 cells exhibited increased levels 
of β1-integrin protein. Therefore, we report for the first time a novel (and potentially important) 
link between increased JAM-A expression and poor clinical outcome in invasive breast tumors.  
Our results suggest that increased expression of JAM-A in tumor cells may ultimately facilitate 
integrin-mediated migratory events at the tumor cell-matrix interface; and warrants further 
exploration as a biomarker of poor prognosis in primary breast cancer or a drug target in the 
future. 
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MATERIALS AND METHODS 
Cell culture. Breast epithelial cell lines were obtained from ATCC (MDA-MB-231, MCF7, 
Hs578T).  Cell lines were grown under standard conditions (DMEM, 10% foetal bovine serum, 
2mM L-glutamine, 50 IU/ml penicillin, 50µg/ml streptomycin).  
 
Antibodies. Anti-human antibodies for Western blotting were sourced as follows: rabbit JAM-A 
(Invitrogen), rat β1- and mouse β4-integrin (BD Biosciences), rabbit E-cadherin (Cell Signaling 
Technologies), mouse actin (Abnova). Immunohistochemistry was conducted using mouse JAM-
A (Abnova); immunofluoresence and inhibition studies using mouse J.10.4 JAM-A (kindly 
donated by Prof. Charles Parkos, Emory University, Atlanta). All JAM-A antibodies detected 
equivalent expression levels by Western blot (not shown). 
 
Tissue microarray (TMA). Duplicate cores from consecutive breast cancer patients with 
invasive primary breast cancer in Malmo University Hospital (1988–1992) were used to construct 
a TMA (with ethical approval from Lund University Review Board) 18.  JAM-A and β1-integrin 
expression data was then determined by immunohistochemistry of this TMA of 270 patient 
specimens with survival data.  
 
Immunohistochemistry. JAM-A and β1-integrin immunohistochemistry (IHC) was performed 
on formalin-fixed paraffin-embedded TMA sections using standard protocols. Briefly, antigen 
retrieval was in citrate buffer pH 6.0 (10 min/95°C); primary antibody incubation (mouse JAM-
A; Abnova or mouse β1-integrin; Novacastra) was for 60 min, secondary antibody incubation 
was for 20 min followed by DAB substrate for 10 min. Membranous expression of JAM-A or β1-
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integrin in tumor cells was scored 0, 1+, 2+, or 3+ based upon staining intensity.  JAM-A results 
were scored blind by 2 observers (one pathologist) and combined. β1-integrin results were scored 
by a pathologist according to the following scheme: 0 = 0% cells, 1 = <10% cells, 2 = 10-50% 
cells, 3 = >50% based upon membranous staining intensity of β1-integrin.  
 
DNA microarray data analysis. The van de Vijver DNA microarray dataset 15 was obtained 
from Rosetta Inpharmatics (www.rii.com). In this breast cancer dataset, expression values for 
25,000 genes had been determined. Normalised JAM-A and β1-integrin log-ratios were 
downloaded with survival and clinicopathological data.  Tumor samples were classified 
according to JAM-A and β1-integrin mRNA expression based on absolute expression analysis p 
values (alpha level of 0.05) 18. 
 
Statistical analysis. χ2 test and Fisher’s exact tests were used for comparison of JAM-A and β1-
integrin expression with other clinicopathological parameters. Kaplan-Meier analysis and the log 
rank test were used to illustrate differences between recurrence-free survival and breast cancer-
specific survival according to JAM-A expression.  Calculations were performed with SPSS-
v12.0.1. 
 
Western blotting. Breast cells were harvested at 80% confluence in 100mM KCl, 3mM NaCl, 
3.5mM MgCl2, 10mM HEPES pH7.4, 1% Triton-X100, protease and phosphatase inhibitor 
cocktails (Sigma).  Samples (25µg) were subjected to reducing SDS-PAGE, transferred to PVDF, 
and immunoblotted for JAM-A, E-cadherin, β1-integrin and β4-integrin. 
 
 8 
Immunofluorescence. Confluent breast cell lines on chamber slides (Nunc, Denmark) were fixed 
in 3.7% paraformaldehyde for 20 min and immunofluorescently-labeled as described 19 using 
JAM-A antibody (5µg/ml), AlexaFluor568-coupled secondary antibody (2µg/ml) and DAPI 
(0.63µg/ml). Images were acquired in a single plane on a Zeiss LSM510-Meta confocal 
microscope. 
 
JAM-A knockdown/over-expression. Three short hairpin (sh-)RNAs targetting JAM-A were 
designed using the siDESIGN tool (www.dharmacon.com). HEK293 cells were transfected with 
pLVTHm vector (Trono Laboratory) containing JAM-A shRNA or empty vector (for gene 
knockdown in MCF7 breast cells); or with LLCIEP vector containing full-length JAM-A or 
empty vector (for gene over-expression in MDA-MB-231 and Hs578T breast cells). Cells were 
also co-transfected with packaging plasmid and envelope plasmid (psPAX2 and pMD2G 
respectively; Trono Laboratory). Live virus was collected, filtered and used to infect 50%-
confluent MCF7, MDA-MB-231 or Hs578T cells for 24 h. Cells were subcultured at 2-3 days. 
 
Scratch-wound assay.  Confluent breast cells were scratch-wounded with a sterile pipette tip and 
allowed to migrate in serum-free media (to ensure that the pro-migratory effects of serum did not 
mask detection of the effects of knockdown or antagonism of JAM-A). Images were acquired on 
a phase contrast microscope linked to a CCD camera and wound diameter was measured at 0, 2, 
4, 6, 8 and 24 h using Scion Image (Scion Corporation, USA).  For indicated experiments, 
monolayers were pre-incubated for 2 hr prior to wounding with anti-human JAM-A (J.10.4 
antibody; 10µg/ml) or culture media for control cell monlayers. 
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Proliferation assay. Proliferation was assessed in breast cells grown on 96-well plates by 
incubation with MTT reagent (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; 
1.25mg/ml) for 4 h followed by solubilization with DMSO. Growth curves of absorbance at 540 
nm versus time were plotted. 
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RESULTS 
High JAM-A expression in breast cancer tissues is significantly associated with poor patient 
prognosis  
Junctional adhesion molecule-A (JAM-A) has important functions in intercellular adhesion 5, and 
its loss in breast cancer cells has recently been observed 14.  To investigate the involvement of 
JAM-A in breast cancer patient survival, we analyzed JAM-A protein expression on an invasive 
breast cancer tissue microarray (TMA) of 270 tumor cores. Cores were scored 0 (negative), 1+, 
2+ or 3+ according to the level of JAM-A membranous staining in tumor cells (Fig. 1A). Scoring 
was performed by 2 independent observers (one pathologist), and the results combined. Tumor 
membranous expression of JAM-A was classified as low (0 (2 tissues), 1+ (62 tissues) or 2+ (122 
tissues)) in 186 tumors (69%) and high (3+) in 84 tumors (31%).  Kaplan-Meier analysis and the 
log-rank test were used to relate JAM-A-expression to breast cancer-specific survival (time from 
diagnosis to death directly attributable to breast cancer burden) and recurrence-free survival.  
High JAM-A protein expression had a statistically significant association with reduced breast 
cancer-specific survival (Fig. 1B; p<0.05). In addition, patients whose tumors had high JAM-A 
protein expression were significantly more likely to develop a recurrence within 5 years 
compared to patients with low JAM-A expression (Fig. 1C; p<0.05).  Examination of the 
relationship between JAM-A expression and other clinico-pathological variables (Table 1) 
revealed that high JAM-A expression was associated with high tumor grade (p<0.05) and 
increased expression of both VEGFR1 (p<0.01) and HER2 (p<0.01).  
 
To confirm our findings, JAM-A mRNA expression was assessed in an independent dataset of 
gene expression information from 295 patients with primary breast cancer 15 (Fig. 2).  All 
patients were younger than 53 years old, had stage I or II primary invasive breast cancer, with 
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approximately 50% being lymph node-positive tumors.  Tumors were classified as high or low 
JAM-A expressers based on array probe-target cDNA hybridization levels.  In this dataset, JAM-
A gene expression was classified as low in 236 tumors (80%) and high in 59 tumors (20%).  
Kaplan-Meier analysis and the log-rank test were used to illustrate differences in overall survival 
(time from diagnosis to death) and metastasis-free survival (time from primary diagnosis to 
diagnosis of secondary cancer) according to JAM-A mRNA expression. High JAM-A mRNA 
expression was associated with reduced overall survival (Fig. 2A; p<0.05) and reduced 
metastasis-free survival (Fig. 2B; p<0.01). Differences in distribution of clinicopathological data 
and tumor characteristics between high JAM-A and moderate/low JAM-A expressing tumors 
were also evaluated using the χ2 test and Fishers exact tests (Table 2). High JAM-A mRNA 
expression was associated with larger tumor size (p<0.05), higher grade (p<0.001), and ER 
negativity (p<0.001).  Tumors in this study were also classified into molecular subtypes using the 
well-validated criteria described by Sorlie et al. 20. This revealed that high JAM-A mRNA levels 
were associated with the basal subtype of breast cancer linked with poor prognosis (p<0.001). 
Finally, high JAM-A mRNA expression was also associated with poor prognosis using the 70-
gene prognostic signature (p<0.001) derived by van’t Veer et al. 21. Together these data confirm 
that over-expression of JAM-A at both mRNA and protein level is associated with poor prognosis 
in breast cancer patients. 
 
JAM-A knockdown or antibody-based inhibition reduces cell migration 
We next reasoned that if JAM-A expression was increased in invasive breast cancer tissues, 
knockdown of high JAM-A expression levels in a cell line model may give clues to explain the in 
vivo mechanisms.  To determine a suitable breast cell line for use in in vitro JAM-A knock-down 
studies, we first investigated the gene- and protein expression of JAM-A via RT-PCR, western 
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blot analyses and immunofluorecence localisation in a panel of breast cell lines. In agreement 
with recently-published work 14, we identified differences in JAM-A expression between breast 
cell lines (data not shown).  
 
MCF7 breast cancer cells expressed high endogenous levels of JAM-A protein, which was shown 
by immunofluorescence confocal microscopy to localize to intercellular tight junctions (data not 
shown). Therefore we knocked down JAM-A protein in MCF7 breast cancer cells, using 
lentiviral technology to transduce cells with 3 different short hairpin (sh)-RNA constructs 
targeting JAM-A (shRNA1, shRNA2, shRNA3). Stably-transduced cell lines were prepared and 
JAM-A knockdown assessed at both gene- and protein expression level.  We demonstrated by 
RT-PCR and western blot analysis that cells stably expressing the shRNA1 construct had similar 
JAM-A levels to empty vector (EV)-expressing control cells, and that shRNA3 mediated a 65% 
decrease in JAM-A expression relative to EV. (Supplemental Fig. 1A & 1B). Notably, shRNA3 
showed comparable levels of JAM-A knockdown in another breast cancer cell line expressing 
high endogenous levels of JAM-A, BT474, indicating the specificity of shRNA3 (data not 
shown).  Based on these results, MCF7 cells transduced with shRNA3 (henceforth designated 
JAM-A-shRNA) were selected for further study. Cells transfected with shRNA1 were chosen as a 
non-functioning (NF) control (henceforth designated NF-shRNA). NF-shRNA controlled for both 
lentiviral effects and also activation of RNAi machinery in transfected cells. Immunofluorescence 
microscopy for JAM-A revealed that its expression was reduced in cells transduced with JAM-A-
shRNA relative to NF-shRNA, but residual protein in the former did still localize at intercellular 
junctions (Supplemental Fig. 1C). 
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As JAM-A had previously been shown to be crucial in adhesion or migration of epithelial cells11 
endothelial cells 22and leukocytes7, we used scratch-wound assays to assess the impact of JAM-A 
depletion on cell migration (Fig. 3). Migration was measured at short time intervals (2, 4, 6 and 8 
hours post-injury) to exclude possible proliferative events. JAM-A-shRNA cells migrated 
significantly slower than NF-shRNA control cells, with respectively 6.9% and 9.4% wound 
closure at 4 hours (Fig. 3A; p<0.05). To further exclude the possibility that proliferative 
differences between NF-shRNA and JAM-A-shRNA cells could influence wound closure, we 
performed MTT assays on both cell lines (Fig. 3B).  Identical growth curves were observed over 
a period of several days, indicating a specific effect of JAM-A knockdown in reducing MCF7 
cell migration, rather than altering growth characteristics.  
 
To confirm that reductions in cell migration resulting from JAM-A knockdown did not result 
from off-target effects of shRNA transduction, we also used an alternative method to antagonize 
JAM-A function. Scratch-wound migration assays were conducted in wild-type MCF7 breast 
cancer cells pre-incubated for 2 hours prior to wounding with an inhibitory JAM-A antibody 
which prevents dimerization of JAM-A (J10.4 23). MCF7 cells pre-incubated with J10.4 migrated 
significantly slower than control cells (Fig. 3C; p<0.01 at 4h).  Experiments repeated on 
consecutive days showed identical trends, so a representative experiment is shown.  Maximal 
differences in migration were seen at 6 hours post-injury, with 8% and 18.5% wound closure in 
J10.4- treated versus control MCF7 cells respectively (p<0.05). This supported our JAM-A 
knockdown data in MCF7 cells, confirming that knockdown or functional antagonism of JAM-A 
decreased the motility of breast cancer cells.  
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JAM-A knockdown reduces β1-integrin expression 
We next sought to investigate possible mechanisms whereby JAM-A knockdown could decrease 
cell motility. Western blot analysis was conducted to determine whether JAM-A knockdown 
concomitantly affected the expression of other proteins important for cell adhesion or migration. 
Expression levels of the cell-cell adhesion protein E-cadherin and the cell-matrix adhesion 
protein β4-integrin were unaffected by JAM-A knockdown (Fig. 3D). However, expression of 
β1-integrin, a cell-matrix adhesion protein required for migration 17 , was dramatically reduced in 
JAM-A-shRNA cells relative to NF-shRNA controls (Fig. 3D). Our results suggest that 
downstream regulation of β1-integrin protein expression represents one possible mechanism for 
JAM-A to regulate cancer cell motility.   
 
High β1-integrin protein (not mRNA) expression tends towards an association with poor 
prognosis in breast cancer  
Results from our western blot analyses suggested that JAM-A over-expression exerts post-
translational effects on β1-integrin expression. We therefore assessed β1-integrin mRNA 
expression in the dataset of gene expression information from 295 patients with primary breast 
cancer15, which in Fig. 2 had demonstrated an association between JAM-A mRNA over-
expression and poor prognosis. As expected, there was no association between high β1-integrin 
mRNA levels and poor prognosis (Fig. 4A). We next immunostained our tissue microarray of 
270 invasive breast cancer cases for β1-integrin protein expression.  High β1-integrin protein 
expression was associated with reduced overall survival, but this was just outside the boundaries 
of statistical significance (p=0.08) (Fig. 4B). However the staining for β1-integrin on formalin-
fixed paraffin tissues was always sub-optimal (despite trying 3 different antibodies and several 
optimization methods), so with better quality staining the association between poor prognosis and 
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over-expression of β1-integrin might be significant. We also saw that 22% of patients expressing 
high levels of JAM-A protein co-expressed high levels of β1-integrin (Fig. 4C). 
 
To further explore the putative association between JAM-A protein over-expression and β1-
integrin protein upregulation, we used lentiviral technology to stably-overexpress JAM-A in 
MDA-MB-231 cells, an invasive breast cancer cell line with very low endogenous levels of 
JAM-A. Western blot analysis revealed that cells overexpressing JAM-A expressed higher levels 
of β1-integrin protein relative to EV control cells (Fig. 4D). Unfortunately however, the vast 
majority of overexpressed JAM-A was seen to localize in the cell cytoplasm rather than at 
intercellular tight junction membranes (Supplemental Fig. 2F). This made it unfeasible to 
directly examine the effect of JAM-A overexpression on functional parameters (such as 
migration) in these cells; since they could not be correlated with observations from the breast 
cancer TMA in which only membranous JAM-A expression had been scored. Nonetheless it did 
suggest some parallel regulation between the total protein expression of JAM-A and β1-integrin; 
in a manner which we hypothesize might influence cancer cell migration. 
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DISCUSSION 
The intercellular tight junction protein JAM-A has been shown to have important physiological 
functions in numerous cellular adhesive processes including leukocyte migration 7, intercellular 
junction assembly 10 and the regulation of cell morphology 11. Re-expression of JAM-A in 
endothelial cells of JAM-A knockout mice has also been reported to prevent spontaneous 
motility, indicating that JAM-A may regulate effectors of motility 13. Furthermore, it has recently 
been reported for the first time that loss of JAM-A may also play a pathophysiological role in 
breast cancer 14.  
 
As we were interested in exploring the role of JAM-A in breast cancer patient survival, we 
analyzed the expression of JAM-A protein in a tissue microarray (TMA) of 270 invasive breast 
cancers. This is, to our knowledge, the first study that has examined patient outcomes in relation 
to levels of JAM-A expression. We found that high levels of JAM-A protein expression were 
associated with high grade tumors, significantly poorer breast cancer-specific survival and poorer 
recurrence-free survival.  
 
Some key points in our study conflict with the recent findings of Naik et al.14 who reported that 
loss of JAM-A expression correlates with breast cancer progression using a small commercially-
available TMA and several breast cell lines.  However our patient dataset was significantly larger 
than that of Naik et al. (270 vs 112 primary breast tumors), and had the additional advantage of 
associated clinico-pathological data and survival data. In particular, our survival data provide 
compelling evidence that JAM-A protein over-expression in invasive breast tumors is associated 
with an unfavourable patient outcome. Nonetheless, we also analyzed JAM-A gene expression in 
a publicly-available invasive breast cancer dataset of 295 invasive breast tumors 15. In support of 
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our TMA data, analysis of this dataset revealed that high levels of JAM-A mRNA significantly 
correlated with reduced overall survival in breast cancer patients. In addition, these data indicated 
that patients whose tumors had high JAM-A gene expression levels were significantly more 
likely to develop metastasis.   
 
It must be noted, however, that over-expression of JAM-A at the gene and protein level may be a 
consequence of breast tumorigenesis rather than a cause of tumor initiation or invasion. 
Therefore, we next sought to mechanistically dissect the functional significance of JAM-A over-
expression in breast cancer via in vitro cell line studies.  We utilised shRNA technology to stably 
knock down the expression of JAM-A in MCF7 breast cancer cells, which express high 
endogenous levels of JAM-A. In colonic epithelial cells, siRNA-mediated knockdown of JAM-A 
expression has been reported to decrease cell adhesion and spreading 11, 22, 24. Knock-down of 
JAM-A expression has also been previously shown to decrease migration of endothelial cells23, 25. 
As migratory capacity is one index of tumor cell dissemination, we therefore assessed the impact 
of JAM-A loss on MCF7 cell migration in scratch wound assays.  Again, in contrast to the breast 
cancer findings of Naik et al., 14 we found that knockdown of JAM-A expression significantly 
decreased the migration of MCF7 breast cancer cells.  In support of our results, a previous report 
has shown that migration of kidney epithelial cells is reduced in the presence of an antibody 
which prevents JAM-A dimerization and downstream signalling 25. The same antibody also 
reduced migration of wild-type MCF7 breast cancer cells in our hands, supporting data from our 
MCF7 cell line in which JAM-A had been stably knocked down using lentiviral technology.  
 
In an attempt to account for reduced cell motility after JAM-A knockdown, we examined the 
expression of various proteins which function in either cell-cell or cell-matrix adhesion. 
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Knockdown of JAM-A in MCF7 cancer cells dramatically reduced the expression of the cell-
matrix protein β1-integrin. This membrane protein links to cytosolic adaptor proteins such as 
paxillin, which in turn affiliate with F-actin fibres to drive cell migration26 .  However there is 
conflict in the literature as to the effects of JAM-A knockdown on levels of β1-integrin protein 
expression. In agreement with our results, JAM-A knockdown by siRNA reportedly reduces β1-
integrin expression in colonic epithelial cells via the small GTPase Rap1 11, 25. However Naik et 
al. mention (as data not shown) that JAM-A downregulation in invasive MDA-MB-231 cells did 
not affect β1-integrin protein levels in their system 14. This discrepancy may have arisen because 
levels of JAM-A are already very low in invasive MDA-MB-231 cells relative to either MCF7 
cells (in our study) or colonic epithelial cells (as used by Mandell et al. 11). Therefore it is a 
possibility that JAM-A levels must be above a certain threshold in order to impact β1-integrin 
protein levels. It must also be stated that migration is a fundamental cellular function, and that 
β1-integrin is only one of several proteins utilized by cells during migration. Therefore it is 
possible that different cell lines utilize alternative pathways of different relative importance for 
migration, or that other pathways may partially compensate for low levels of JAM-A and/or β1-
integrin in order to influence cell migration. 
 
To further explore the possible link between of JAM-A and β1-integrin in breast cancer, we 
analyzed the expression of β1-integrin protein in our TMA of 270 invasive breast cancers. High 
β1-integrin protein expression tended to associate with reduced overall survival (p=0.08).  We 
found that 22 % of patients expressing high levels of JAM-A also expressed high levels of β1-
integrin.  However, this association was not statistically significant. One potential reason for this 
is that we observed very poor β1-integrin staining in most tissue cores. Only 4% of cores stained 
for β1-integrin were classified as score 2 or 3. This is in contrast to results for JAM-A 
 19 
membranous staining, where 31% (84 of 270) were classified as score 3 alone. These low levels 
of β1-integrin staining suggest that IHC antibodies for detection of β1-integrin may not yet be of 
sufficient quality for this technique; potentially accounting for non-significant associations 
between poor survival and concomitant over-expression of JAM-A and β1-integrin. In fact there 
is little published work reporting the use of IHC to assess β1-integrin protein levels in formalin-
fixed paraffin-embedded clinical tissues. It is likely that β1-integrin staining in fresh-frozen 
patient tissues, although more difficult to procure in large numbers, would be more informative. 
 
In a parallel attempt to probe possible associations between over-expression of JAM-A and  β1-
integrin, we also performed stable over-expression of JAM-A in two breast cancer cell lines with 
low endogenous JAM-A expression (MDA-MB-231 and Hs578T; supplemental Fig 2). 
Although gene and protein levels of JAM-A increased significantly in both cell lines, JAM-A 
protein localisation was not, however, restricted to intercellular TJ membranes as in cell lines 
endogenously expressing JAM-A.  Only a small minority of transfected cells showed increases in 
JAM-A in the cell cytoplasm.  We therefore felt that performing functional assays (such as 
migration) with these lines would not be informative given that JAM-A should localize at tight 
junction membranes. In addition, our immunohistochemical analysis of JAM-A protein in patient 
TMAs scored only membrane-associated JAM-A; and therefore clinical data could not be directly 
compared to functional data from JAM-overexpressing cell lines.  However, MDA-MB-231 cells 
over-expressing JAM-A did show an increase in β1-integrin protein expression, supporting our 
hypothesis that JAM-A and β1-integrin may be two components of a signalling pathway in breast 
cancer cells that culminates in increased migration. 
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As β1-integrin is required for cell migration in some cells 17, our study suggests that loss of β1-
integrin downstream of JAM-A knockdown may contribute to observed reductions in migration 
in our cancer cell line models. Conversely, since over-expression of JAM-A appears to 
upregulate β1-integrin expression, this may be one potential mechanism driving enhanced cancer 
cell motility. As tumor cell motility is required early in the metastatic process, we speculate that 
increased JAM-A expression in invasive breast cancer tissues will in parallel upregulate β1-
integrin protein expression and ultimately promote motility. In support of an important effector 
role for β1-integrin, this protein has long been implicated in breast cancer malignancy via effects 
on growth, apoptosis, migration and invasion 27.  In vitro experiments using 3-dimensional 
cultures of breast cancer cells show that inhibitory antibodies to β1-integrin induce disorganized 
aggregates of malignant cells to undergo a phenotypic reversion, ultimately recovering a 
structural organization in vitro which is reminiscent of normal breast acini in vivo 16, 28.  It will be 
interesting to investigate if JAM-A is an important upstream regulator of β1-integrin during 
migration.  
 
We sum up our study on the potential role of JAM-A in breast cancer by considering at least two 
distinct possibilities. One possible explanation is that loss of JAM-based cell-cell adhesion in 
cancer facilitates cell dissociation and promotes motile behaviour (as recently reported by Naik et 
al. 14). However our data suggest a second possibility, that over-expression of JAM-A in invasive 
breast cancer patient tissues promotes cell motility via downstream effects on β1-integrin. This 
may mean that in some breast cancers JAM-A has a more important role in regulating 
pathophysiological events at the cell-matrix interface rather than at the cell-cell interface. 
However a “balancing act” of JAM-A protein expression in normal versus tumor states is likely 
to crucial and could explain discrepancies between our in vivo and recently published in vitro14 
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results. Low JAM-A expression in breast epithelial cells is likely to impair cellular adhesion and 
polarity, favouring tumor initiation.  Therefore increasing JAM-A expression in MDA-MB-231 
cells, which express low levels of JAM-A, may account for reported reductions in cancer cell 
invasion 14. Conversely, reducing high levels of JAM-A expression in breast cancer cells, as we 
have shown in MCF7 breast cancer cells, may decrease cell motility through downstream effects 
on β1-integrin.  Given the complexity of this situation in relation to human breast cancer, further 
research is needed to elucidate the potential downstream influences of altered JAM-A signalling 
on β1-integrin function and tumor cell migratory events.  
 
In conclusion, our data suggest for the first time a novel link between increased JAM-A 
expression and reduced survival of breast cancer patients.  JAM-A may ultimately be a relevant 
breast cancer biomarker. Our results with a JAM-A inhibitory antibody suggest that JAM-A 
dimerization is required for downstream promotion of cancer cell migration.  If so, it is tempting 
to speculate that JAM-A may be a promising future target for biological antibody therapies 
similar to those targeting breast tumors over-expressing HER2 29.  
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TABLES 
Table 1: Clinicopathological features stratified according to JAM-A protein expression 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Values in parentheses indicate percentages. IDC = invasive ductal carcinoma, ILC = 
invasive lobular carcinoma, NHG = Nottingham Histological Grade, ER = estrogen 
receptor, PR = progesterone receptor, VEGF = vascular endothelial growth factor, 
VEGFR1 = vascular endothelial growth factor receptor 1, VEGFR2 = vascular endothelial 
growth factor receptor 2. 
 
Variable N High JAM-A (%) Low JAM-A (%) P value 
Age (years) 272   0.741 
n  84 188  
Median (Range)  63.8 (35 - 89) 64 (36 - 96)  
     
Tumor Diameter (mm)  272   0.262 
T1 (1-20mm)  49 (58.3) 123 (65.4)  
T2 (>20mm)  35 (41.7) 65 (34.6)  
     
Histological Subtype 272   0.551 
Indeterminate  10 (11.9) 11 (5.9)  
IDC  54 (64.3) 132 (70.2)  
ILC  11 (13.1) 26 (13.8)  
Tubular  6 (7.1) 10 (5.3)  
Medullary  2 (2.4) 4 (2.1)  
Mucinous  1 (1.2) 5 (2.7)  
     
NHG 200   0.038 * 
I - II  47 (56) 129 (69) 
 
III  37 (44) 58 (31)  
     
Lymph Node Status 244   0.183 
N0 Negative  43 (56.6) 110 (65.5)  
N1+ Positive  33 (43.4) 58 (34.5)  
     
ER Status 265   0.16 
Negative (1-10%)  16 (19.8) 24 (13)  
Positive (11-100%)  65 (80.2) 160 (87)  
     
PR Status 216   0.325 
Negative (1-10%)  29 (43.3) 54 (36.2)  
Positive (11-100%)  38 (57.7) 95 (63.8)  
     
Ki67 Status 264   0.081 
Negative (1-10%)  25 (30.5) 76 (41.8)  
Positive (11-100%)  57 (69.5) 106 (58.2)  
     
VEGF 198   0.523 
0-2+  55 (83.3) 105 (79.5)  
3+  11 (16.7) 27 (20.5)  
     
VEGFR1 243   0.008 ** 
0-2+  36 (48) 111 (66.1) 
 
3+  39 (52) 57 (33.9)  
     
VEGFR2 196   0.848 
0-2+  54 (87.1) 118 (88.1)  
3+  8 (12.9) 16 (11.9)  
     
HER2 189   0.003 ** 
0-2+  46 (82.1) 127 (95.5) 
 
3+  10 (17.9) 6 (4.5)  
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Table 2: 
JAM-A mRNA expression in the van de Vijver microarray dataset according to various 
clinicopathological and molecular characteristics 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
JAM-A 
High (%) 
(n = 59) 
JAM-A 
Low/Negative (%) 
(n = 236) 
P value  
(Χ2 test) 
 
Age, years   0.682 
  Median (range) 43.5 (28 - 52) 44 (26 - 53)  
  < Median (26-44) 28 (47.5) 105 (44.5)  
  > Median (44-53) 31 (52.5) 131 (55.5)  
    
Tumor Diameter, mm   0.041 * 
  T1 (1-20mm) 24 (40.7) 131(55.5) 
 
  T2 (>20mm) 35 (59.3) 105(44.5)  
    
Grade   <0.001 *** 
  I 7 (11.9) 68 (28.8) 
 
  II 15 (25.4) 86 (36.4)  
  III 37 (62.7) 82 (34.7)  
    
Lymph Node Status    0.727 
  Negative 29 (49.2) 122 (51.7)  
  Positive 30 (50.8) 114 (48.3)  
    
ER Status   <0.001 *** 
  Negative 30 (50.8) 39 (16.5) 
 
  Positive 29 (49.2) 197 (83.5)  
    
Molecular Subtype 20    
  Normal 0 (0.0) 31 (13.1) 
 
  Luminal A 9 (15.3) 79 (33.5)  
  Luminal B 18 (30.5) 63 (26.7)  
  Basal 20 (33.9) 25 (10.6) <0.001 *** 
  ERBB2 12 (20.3) 38 (16.1)  
    
70-Gene Signature21   <0.001 *** 
  Good Prognosis 7 (11.9) 108 (45.8) 
 
  Poor Prognosis 52 (88.1) 128 (54.2)  
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FIGURE LEGENDS 
Figure 1: High levels of JAM-A protein are associated with poor prognosis in breast cancer 
patients 
A. 270 invasive breast cancer TMA cores were scored either 0, 1+, 2+ or 3+ based on levels of 
membranous JAM-A protein expression.  Kaplan-Meier analysis comparing tumors scored 0, 1+ 
or 2+ (JAM-A low) to those scored 3+ (JAM-A high) for breast cancer-specific survival (B.) and 
recurrence-free survival at 5 years (C.) based upon JAM-A protein expression.   
 
Figure 2: High levels of JAM-A mRNA are associated with poor prognosis in breast cancer 
patients 
Kaplan-Meier estimate of overall survival (A.) and probability of metastasis as first event (B.) 
with low versus high mRNA expression of JAM-A in the van de Vijver et al. (2002) DNA 
microarray dataset, comprised of data from 295 primary invasive breast tumors.   
 
Figure 3: JAM-A knockdown or antibody-based inhibition reduces migration of MCF7 
cells 
A. Migration of JAM-A-shRNA MCF7 cells and NF-shRNA cells were compared using scratch-
wound assays photographed at 0, 2, 4, 6, and 8 hours post-injury. Error bars refer to standard 
deviation from the mean (S.D.) and represent triplicate values in a representative experiment. B. 
MTT proliferation assays were conducted on NF-shRNA and JAM-A-shRNA MCF7 cell lines.  
Error bars refer to S.D. and represent five internal replicates.  C. Scratch-wound assays were 
used to assess the migration of wild-type MCF7 cells pre-incubated for 2 hours with 10µg/ml 
JAM-A inhibitory antibody (J.10.4) or for controls, media alone. Error bars refer to S.D. and 
represent triplicate values in a representative experiment.  D. Western blot analysis of a panel of 
 30 
proteins was conducted on NF-shRNA and JAM-A-shRNA MCF7 cell lines. Assessment of 
actin expression was performed to control for protein loading. Note: Unpaired Student’s t-tests 
were performed to assess differences between cell lines in functional assays A, B and C. 
 
Figure 4: β1-integrin expression in breast cancer  
A.  Kaplan-Meier estimate of overall survival with low versus high mRNA expression of β1-
integrin in the van de Vijver et al. (2002) DNA microarray dataset, comprised of data from 295 
primary invasive breast tumors. B. Kaplan-Meier estimate of overall survival with low versus 
high protein expression of β1-integrin in the TMA of 270 patients used to determine JAM-A 
expression in Fig.1. Note: five patients cores were unsuitable for analysis therefore n = 265. C. 
Number of tissues from invasive breast cancer TMA (n = 270) which overexpressed JAM-A 
versus JAM-A plus β1-integrin. D. Western blot analysis showing the expression of JAM-A and 
β1-integrin in MDA-MB-231 empty vector control and MDA-MB-231 JAM-A over-expressing 
cells. 
 
Supplemental Figure 1: JAM-A knockdown in MCF7 breast cells 
A. MCF7 cells were transduced with pVTLH containing JAM-A hairpins shRNA1, shRNA2 or 
shRNA3 or empty pLVTH vector (EV), and analyzed for levels of JAM-A gene expression by 
TaqMan RT-PCR. B. JAM-A protein expression levels in EV and shRNA-JAM-A MCF7 lines as 
determined by Western blot analysis. C. Immunofluorescent localization of JAM-A protein in 
MCF-7 cells expressing non-functioning shRNA1 (NF-shRNA) or JAM-A shRNA3 (JAM-A-
shRNA).   
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Supplemental Figure 2: Over-Expression of JAM-A in Breast Cancer Cell Lines  
Western blot comparison of JAM-A protein expression in Hs578T (A.) and MDA-MB-231 (B.) 
empty vector and JAM-A over-expressing cell lines. TaqMan RT-PCR results showing JAM-A 
mRNA expression in Hs578T (C.) and MDA-MB-231 (D.) empty vector and JAM-A over-
expressing cell lines.  Fold-normalized JAM-A gene expression in the over-expressing cell line 
relative to the empty vector control cell line is plotted on the Y-axis. Confocal 
immunofluorescence micrographs show JAM-A, and F-actin protein localization patterns in 
Hs578T (E.) and MDA-MB-231 (F.) empty vector and JAM-A over-expressing cell lines.  
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Figure 2: McSherry et al. 
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 Figure 3: McSherry et al. 
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Figure 4: McSherry et al. 
0
5
10
15
20
25
30
35
Overexpressing
JAM-A
Overexpressing
JAM-A and ß1-
integrin
%
 
Ti
ss
u
es
 
fro
m
 
in
va
si
v
e 
br
ea
st
 
ca
n
ce
r 
TM
A
p = 0.9525 (NS)
ß
B.ß
p = 0.085 (NS)
ß
ß
B.A.
mRNA Protein
D.C.
β1-integrin 
JAM-A
M
DA
-
M
B-
23
1_
EV
M
DA
-
M
B-
23
1_
JA
M
-
A
ß
%
 
Ti
ss
u
es
 
fro
m
 
in
va
si
v
e 
br
ea
st
 
ca
n
ce
r 
TM
A
M
DA
-
M
B-
23
1_
EV
M
DA
-
M
B-
23
1_
JA
M
-
A
β1-integrin 
JAM-A 
M
DA
-
M
B-
23
1_
EV
 
M
DA
-
M
B-
23
1_
JA
M
-
A 
 36 
Supplemental Figure 1: McSherry et al. 
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Supplemental Figure 2: McSherry et al.
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